Viyash Scientific Limited
207.75
INR
-6.50
(-3.03%)
ISIN
INE807F01027
Return %
Stock
S&P 500
1Y
0.95
14.20
3Y
98.61
81.12
5Y
11.84
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Haribabu Bodepudi
- Full Time Employees
- 4,131
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Srivallis Corporate Hyderabad MA India 500033
- IPO Date
- Mar 10, 2016
- Website
- viyash.com
- Similar Companies
- Business
- Viyash Scientific Limited; an India-based integrated pharmaceutical and life sciences company, specializes in analytical and bioanalytical services, animal health products, and a diversified portfolio spanning active pharmaceutical ingredients, finished dosage formulations, and therapeutic supports. The company develops and validates analytical methods, conducts stability testing, and performs microbiology services for APIs and finished products across multiple dosage forms, leveraging customer-developed, in-house, and pharmacopoeia-compliant approaches. Through its subsidiaries, including Alivira Animal Health, it distributes companion animal products and extends its analytical service offerings to pharmaceutical and life sciences customers. The group maintains a multi-continental manufacturing footprint and a global client base, with operations in India and international facilities, underpinning a broad market reach across Europe, Asia, and the rest of the world. Founded in 1999 and headquartered in Mumbai, Viyash Scientific Limited operates within the pharmaceutical, nutraceutical, and life sciences segments, delivering integrated solutions that cover product development, analytical testing, quality assurance, and regulatory support for API manufacturers, contract research organizations, and end-user markets. The company emphasizes ongoing expansion through strategic partnerships, product launches, and capacity enhancements, aiming to strengthen its position in animal health, dermatology, anti-infectives, NSAIDs, and dermatological therapies while pursuing efficiencies across its integrated operations. Key recent developments include strategic alliances and potential acquisitions or mergers to consolidate its position in analytical services and animal health distribution, alongside ongoing investments in research and development, manufacturing capabilities, and regional market expansion. Viyash Scientific maintains a structured product and service catalog across categories such as analytical solutions (method validation, stability programs, microbiology testing), bioanalytical services, animal health products (therapeutics for livestock, poultry, and companion animals), active pharmaceutical ingredients, finished dosage formulations, nutraceuticals, dermatology and anti-infective therapies, and contract research services, supported by a global distribution network and regulatory-compliance-oriented operations. By focusing on quality, regulatory alignment, and end-to-end support, the company positions itself as a provider of integrated solutions for pharmaceutical, animal health, and consumer health sectors across multiple geographies.